• By ICR Secretariat
  • Posted Thursday, September 9, 2021

NICE recommends Novartis’ Cosentyx for children with severe psoriasis

http://www.pharmatimes.com/news/nice_recommends_novartis_consentyx_for_children_with_psoriasis_1376182

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.